Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617955 · ClinicalTrials.gov registry record
Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates
A clinical trial, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- 462
- Enrollment target
NCT00617955: Completed study, sponsored by State University of New York - Upstate Medical University.
NCT00617955 is a clinical trial that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 462 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617955 has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- 462 participants
- Enrollment target
Study Summary
The dept. of Anesthesiology currently has a database of subjects whom had surgery and received either Aprotinin or Amicar in the OR. The current viewpoint is that Aprotinin is more harmful than Amicard. In an effort to see what the long term outcomes were for subjects whom had surgery here at Upstate, it was decided to look at long term death rates to see if any differences. A student t-test will be used to determine statistical significance where a p value of \<0.05 will be deemed significant. Using data from 462 subjects that had undergone cardiac surgery at SUNY Upstate Medical University, CABG only and the long term mortality rate from the Mangano, et.al. publications, the unadjusted mortality for the two drugs are Aprotinin 5.4% and Amicar 1.2%. A power analysis was performed using the hospital mortality rates of 5.4% and 1.2% with the sample size in the propensity data and a p-value of 0.05. The result was a power of 81.7%.
Interventions
- DRUG Aprotinin
- DRUG Amicar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-06 |
What the finished NCT00617955 record still lists
NCT00617955 is an observational study that tracks outcomes without assigning an intervention. The registered 462 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Aprotinin is the first listed.
NCT00617955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00617955 about?
NCT00617955 is a clinical study titled "Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates". The dept. of Anesthesiology currently has a database of subjects whom had surgery and received either Aprotinin or Amicar in the OR. The current viewpoint is that Aprotinin is more harmful than Amicard. In an effort to see what the long term outcomes were for subjects whom had surgery here at Upstat...
What is the current status of trial NCT00617955?
This trial is currently completed. The enrollment target is 462 participants. The study started on 2007-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00617955?
The interventions under investigation include: Aprotinin (DRUG), Amicar (DRUG).
Who is sponsoring clinical trial NCT00617955?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia